Floatz Rating
B60/100
Confidence
Indicative
Sponsor
First Affiliated Hospital of Wannan Medical College
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06225752CT.gov Probucol for Symptomatic Intracranial and Extracranial Artery Stenosis | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Transient Ischemic Attack
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Probucol (this asset) | First Affiliated Hospital of Wannan Medical College | P3 | B · 60 |
| Aspirin | Sichuan Provincial People's Hospital | P4 | BBB |
| Clopidogrel | Sichuan Provincial People's Hospital | P4 | BBB |
| Ticagrelor | Mazandaran University of Medical Sciences | P3 | BBB |
| Cilostazol | Stanford University | P4 | BBB |
| Rivaroxaban | General Hospital of Shenyang Military Region | P4 | BBB |
| Apixaban | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | P4 | BBB |
| 3-N-BUTYLPHTHALIDE | Peking Union Medical College Hospital | P4 | BBB |
| Warfarin | Seoul National University Hospital | P4 | BB |
+34 more in the Transient Ischemic Attack cohort
Other indications for Probucol
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Brain Ischemia | — | P4 | BB · 65 |
| Intracerebral Hemorrhage | — | P4 | BB · 65 |
| Cerebral Atherosclerosis | — | P4 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Probucol in Transient Ischemic Attack. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/probucol-transient-ischemic-attack
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →